About Clarus Ventures
Clarus Ventures is a private equity firm founded in 2005. It is primarily based in Cambridge, United States.
Overall Clarus Ventures portfolio has seen 3 acquisitions, namely NanoString, Pearl Therapeutics and Sarcode Bioscience. A lot of funds co-invest with Clarus Ventures, with names like Global Life Science Ventures sharing a substantial percentage of its portfolio.
Clarus Ventures has a team of 7 people, including 3 partners.
Key Metrics
Clarus Ventures' Portfolio
They have invested in a total of 3 companies. Their most recent investment was in Pearl Therapeutics (Series D round) on Apr 01, 2013. Here is the most recent investment by Clarus Ventures:Team profile of Clarus Ventures
Clarus Ventures has a team of 7 members including 3 Partners, 1 Venture Partner and 1 Principal located in United States and Taiwan. Clarus Ventures' team does not sit on the board of any company as of now.Here is a list of all team members in Clarus Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | Boston | - | ||
Partner | - | - | ||
Venture Partner | San Francisco | - | ||
Principal | Boston | - | ||
Advisor | Cambridge | - |
Co-investors of Clarus Ventures
Over the past 21 years, 5 investors have co-invested in Clarus Ventures's portfolio companies.
- Top Co-investors of Clarus Ventures: 5 investors entered a company along with Clarus Ventures. These include investors like Global Life Science Ventures (1 company).
Clarus Ventures News
•
ChromaCode Announces Appointment of Mark McDonough as ChairmanBioSpace•Jan 10, 2024•ChromaCode, Clarus Ventures
•
Blackstone Forms New Biotech With Initial $250M InvestmentLaw360•Feb 27, 2019•Anthos Therapeutics, Blackstone, Novartis, Clarus Ventures and 1 other
•
Blackstone Announces Agreement to Acquire Clarus, a Leading Life Sciences Investment FirmBusiness Wire•Oct 04, 2018•Blackstone, Clarus, Clarus Ventures
•
Clarus Appoints Former Ariad CEO Paris Panayiotopoulos as Operating Partner and Member of its Investment TeamPR Newswire•Apr 23, 2018•Clarus Ventures
•
BRIEF-Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22Reuters•Apr 05, 2018•Catabasis Pharmaceuticals, Clarus Ventures
•
•
•
Gritstone Oncology Secures $92.7 Million in Series B Financing | Business WireBusiness Wire•Sep 07, 2017•Gritstone Oncology, LAV Asset Management, Versant Ventures, The Column Group and 4 others
•
•
Graybug Vision Raises $44.5M in Series B Funding |FinSMEsFinSMEs•May 02, 2016•Graybug Vision, Deerfield, Orbimed, Clarus Ventures and 1 other
